U.S. markets close in 5 hours

BriaCell Therapeutics Corp. (BCTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.4900+0.0600 (+1.35%)
As of 10:58AM EDT. Market open.

BriaCell Therapeutics Corp.

Bellevue Centre
235 West 15th Street Suite 300
West Vancouver, BC V7T 2X1


Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. William V. Williams M.D.CEO, Pres & Director283.44kN/A1956
Dr. Charles Louis Wiseman M.D., FACPFounder73.1kN/A1946
Mr. Gadi Levin B.Com., C.A., M.B.A., CPA, MBACFO & Corp. Sec.52.5kN/A1973
Ms. Farrah DeanMang. of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Corporate Governance

BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.